Get the Stockscreener App
103.27
1.56%
1.59
Rhythm Pharmaceuticals Inc stock is traded at $103.27, with a volume of 711.77K.
It is up +1.56% in the last 24 hours and up +17.59% over the past month.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
See More
Previous Close:
$101.68
Open:
$102
24h Volume:
711.77K
Relative Volume:
1.04
Market Cap:
$6.86B
Revenue:
$136.86M
Net Income/Loss:
$-168.69M
P/E Ratio:
-36.75
EPS:
-2.81
Net Cash Flow:
$-113.49M
1W Performance:
+5.80%
1M Performance:
+17.59%
6M Performance:
+84.18%
1Y Performance:
+133.70%
1-Day Range:
$101.51
$104.87
1-Week Range:
$93.64
$104.87
52-Week Range:
$44.31
$104.87
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
103.27 | 6.52B | 136.86M | -168.69M | -113.49M | -2.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Initiated | Goldman | Buy |
| Jul-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-07-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-05-25 | Resumed | Stifel | Buy |
| Jan-02-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
FDA accepts Rhythm Pharmaceuticals’ setmelanotide application for review - Investing.com
Rhythm Pharmaceuticals Announces FDA Acceptance of sNDA for Setmelanotide in Acquired Hypothalamic Obesity - GlobeNewswire
19.8% BMI Reduction: Rhythm's Breakthrough Obesity Drug Gets Fast-Track FDA Review for Rare Disease - Stock Titan
Ichimoku Cloud Indicates Uncertainty Around Rhythm Pharmaceuticals Inc.Weekly Trend Recap & Pattern Based Trade Signal System - classian.co.kr
New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data - Benzinga
Rhythm Pharmaceuticals Inc. May Be Forming Higher Low — Chartwatchers AlertPrice Action & Community Consensus Picks - newsyoung.net
Biotech's Big Comeback: 4 Stocks Poised to Ride the Resurgence (MDCX, ARVN, RYTM, ENTA) - MarketScreener
Rhythm Pharmaceuticals prices $175M stock offering - MSN
Leerink Partners Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $102 - 富途牛牛
Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study - TipRanks
Insider Selling at Rhythm Pharmaceuticals: Liquidity or Lack of Confidence? - AInvest
Rhythm Pharmaceuticals Insider Sold Shares Worth $2,704,624, According to a Recent SEC Filing - MarketScreener
Rhythm Pharma CFO Smith sells $2.7m in shares By Investing.com - Investing.com South Africa
Rhythm pharmaceuticals corporate controller sells $142,500 in shares By Investing.com - Investing.com Australia
Rhythm pharmaceuticals corporate controller sells $142,500 in shares - Investing.com
Rhythm Pharmaceuticals Executives Make Significant Stock Trades in August 2025. - AInvest
Rhythm Pharmaceuticals Insider Sold Shares Worth $358,891, According to a Recent SEC Filing - MarketScreener
Shulman Joseph of Rhythm Pharma sells $358,891 in shares By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals CTO Joseph Buys, Sells Shares in August 2025 - AInvest
Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment - TipRanks
Rhythm Pharmaceuticals stock hits all-time high at 95.05 USD - Investing.com
Rhythm Pharmaceuticals stock hits all-time high at 95.05 USD By Investing.com - Investing.com Australia
Can Rhythm Pharmaceuticals’ (RYTM) Revenue Growth Offset Persistent Losses in Its Path to Profitability? - simplywall.st
Rhythm Pharmaceuticals Inc. Forms Bullish Flag — Upside AheadSmart Allocation Stock Pick Insights Gaining Interest - beatles.ru
Rhythm Pharmaceuticals and the Impending Lock-Up Expiry: A Catalyst for Shareholder Value Realization - AInvest
Rhythm Pharmaceuticals: Unlocking Value as Key Lock-Up Expiry and Setmelanotide Regulatory Milestones Loom - AInvest
Rhythm Pharmaceuticals: A Post-Lock-Up Opportunity with Strong Catalysts in Q3 2025 and Beyond - AInvest
Rhythm Pharmaceuticals Lock-Up Agreement Ends on August 9, 2025 - AInvest
Pediatric Obesity Market Expected to Experience Major Growth by 2034, According to DelveInsight | VIVUS LLC, Novartis, Rhythm Pharmaceuticals, Jack Yanovski - The Globe and Mail
Certain Performance Stock Units of Rhythm Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 9-AUG-2025. - MarketScreener
12 Analysts Weigh In on Rhythm Pharmaceuticals: A Comprehensive Analysis of Ratings and Price Targets - AInvest
Rhythm Pharmaceuticals Exceeds Q2 Expectations, Maintains Buy Rating - AInvest
Leerink Partners Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $102 - 富途牛牛
Strong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals - TipRanks
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q2 2025 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals stock price target raised to $100 from $80 at H.C. Wainwright - Investing.com Canada
HC Wainwright Raises PT to $100, Maintains Buy Rating on Rhythm Pharmaceuticals. - AInvest
Loss-Making Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Expected To Breakeven In The Medium-Term - Yahoo Finance
Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - TipRanks
Positive Outlook on Rhythm Pharmaceuticals: Strong Growth Potential and Strategic Advancements Support Buy Rating - TipRanks
Guggenheim Raises Rhythm Pharmaceuticals Buy Rating, PT to $120 - AInvest
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates - MSN
Citizens JMP raises Rhythm Pharmaceuticals stock price target to $135 on growth - Investing.com Canada
Rhythm Pharmaceuticals shares rise 3.30% premarket after reporting Q2 2025 earnings. - AInvest
Rhythm Pharmaceuticals Inc (RYTM) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Rhythm Pharmaceuticals Inc (RYTM) Q2 2025 Earnings Call Highligh - GuruFocus
Rhythm Pharmaceuticals Reports Strong Q2 2025 Growth - TipRanks
Rhythm Pharmaceuticals Q2 Revenue Surpasses Estimates, Up 67% YoY - AInvest
Rhythm Pharmaceuticals: Unlocking Value in Rare Disease Innovation and Commercial Scalability - AInvest
Rhythm Pharmaceuticals Achieves 29% QoQ Revenue Growth, Sets Sights on HO Regulatory Filings - AInvest
Rhythm Pharmaceuticals' Q2 2025: Navigating Key Contradictions in Trial Design, Stock Compensation, and Market Dynamics - AInvest
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rhythm Pharmaceuticals Inc Stock (RYTM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Smith Hunter C | Chief Financial Officer |
Aug 13 '25 |
Option Exercise |
6.88 |
3,477 |
23,922 |
120,392 |
| Smith Hunter C | Chief Financial Officer |
Aug 12 '25 |
Sale |
96.33 |
24,611 |
2,370,832 |
116,915 |
| Smith Hunter C | Chief Financial Officer |
Aug 13 '25 |
Sale |
96.00 |
3,477 |
333,792 |
116,915 |
| German Christopher Paul | Corporate Controller & CAO |
Aug 12 '25 |
Option Exercise |
28.39 |
1,500 |
42,585 |
1,922 |
| German Christopher Paul | Corporate Controller & CAO |
Aug 12 '25 |
Sale |
95.00 |
1,500 |
142,500 |
922 |
| Shulman Joseph | Chief Technical Officer |
Aug 11 '25 |
Option Exercise |
6.80 |
3,984 |
27,091 |
12,493 |
| Shulman Joseph | Chief Technical Officer |
Aug 11 '25 |
Sale |
90.08 |
3,984 |
358,891 |
8,509 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):